Want to see IN:ANTHEM full AI Analyst Report?
Top Page
Anthem Biosciences Limited
(ANTHEM)
Select Model
Select Model
Rating:77Outperform
Price Target:
₹993.00
▲(28.98% Upside)
Action:Reiterated
Date:08/21/26
The score is driven primarily by strong financial performance (rapid growth, improving free cash flow, and low leverage) and supportive technical momentum (price above key moving averages with positive MACD). These positives are meaningfully offset by a stretched valuation (P/E 85.32) and near-overbought stochastic levels, which increase sensitivity to any growth slowdown.
Positive Factors
Strong Revenue and Profit Growth
Rapid revenue growth combined with higher net income indicates strong customer demand and operating execution. If supported by recurring contract research and manufacturing programs, this can expand the company’s earnings base over the next several quarters.
Negative Factors
Uncertain Sustainability of Exceptional Growth
Growth at this unusually high rate may reflect an elevated comparison effect, project timing, or temporary mix changes. Without additional periods of results, investors cannot yet determine whether the expansion represents a durable acceleration in recurring demand.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue and Profit Growth
Rapid revenue growth combined with higher net income indicates strong customer demand and operating execution. If supported by recurring contract research and manufacturing programs, this can expand the company’s earnings base over the next several quarters.
Read all positive factors
Anthem Biosciences Limited (ANTHEM) vs. iShares MSCI India ETF (INDA)
Market Cap
₹491.01B
Dividend Yield0.23%
Average Volume (3M)144.08K
Price to Earnings (P/E)85.0
Beta (1Y)0.97
Revenue GrowthN/A
EPS GrowthN/A
CountryIN
Employees2,282
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)4.57
Shares Outstanding563,408,000
10 Day Avg. Volume43,734
30 Day Avg. Volume144,079
Financial Highlights & Ratios
PEG Ratio1.99
Price to Book (P/B)12.10
Price to Sales (P/S)17.33
P/FCF Ratio52.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹900.00Price Target Upside16.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)12.72
Revenue Forecast (FY)₹25.27B
Anthem Biosciences Limited Business Overview & Revenue Model
Company Description
Anthem Biosciences Ltd. operates as a technology-driven organization specializing in contract research, development, and manufacturing (CRDMO). The company's activities are organized into two primary divisions: CRDMO services and the production of...
How the Company Makes Money
Anthem Biosciences primarily makes money by providing outsourced services to pharmaceutical and biotechnology companies under contract-based engagements. Its main revenue streams typically include: (1) Contract Research and Development (CRD/CRO) s...
Anthem Biosciences Limited Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
90
Very Positive
Cash Flow
84
Very Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 |
|---|---|---|---|
Income Statement | |||
| Total Revenue | 10.33B | 21.24B | 18.45B |
| Gross Profit | 6.33B | 8.95B | 11.01B |
| EBITDA | 4.75B | 8.34B | 7.56B |
| Net Income | 2.56B | 5.92B | 4.51B |
Balance Sheet | |||
| Total Assets | 32.84B | 34.29B | 28.08B |
| Cash, Cash Equivalents and Short-Term Investments | 11.00B | 9.40B | 7.32B |
| Total Debt | 1.10B | 539.24M | 1.13B |
| Total Liabilities | 5.32B | 3.87B | 3.98B |
| Stockholders Equity | 27.53B | 30.43B | 24.10B |
Cash Flow | |||
| Free Cash Flow | 3.09B | 7.06B | 1.04B |
| Operating Cash Flow | 6.34B | 9.17B | 4.18B |
| Investing Cash Flow | -2.37B | -7.81B | -1.52B |
| Financing Cash Flow | -390.05M | -331.04M | -1.34B |
Anthem Biosciences Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | ₹145.27B | 51.00 | ― | 0.22% | 18.30% | 10.86% | |
77 Outperform | ₹491.01B | 85.02 | ― | 0.26% | ― | ― | |
77 Outperform | ₹491.21B | 46.03 | ― | 2.27% | 5.75% | 12.41% | |
71 Outperform | ₹484.60B | 37.02 | ― | 0.23% | 10.59% | 68.21% | |
60 Neutral | ₹980.48B | 88.99 | ― | 0.12% | 22.62% | 114.66% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | ₹43.41B | 58.95 | ― | 0.03% | 16.70% | 18.73% |
* General Sector Average
IN:ANTHEM
Anthem Biosciences Limited
871.50
30.74
3.66%
IN:GLAXO
GlaxoSmithKline Pharmaceuticals Limited
2,899.60
169.74
6.22%
IN:GUFICBIO
Gufic Biosciences Limited
432.90
54.45
14.39%
IN:IPCALAB
IPCA Laboratories Limited
1,910.45
515.45
36.95%
IN:LAURUSLABS
Laurus Labs Ltd.
1,814.65
943.19
108.23%
IN:RAINBOW
Rainbow Childrens Medicare Limited
1,430.30
-90.07
-5.92%
Anthem Biosciences Limited Corporate Events
Anthem Biosciences shareholders clear accounts, dividend and board reappointment at 20th AGM
Jul 22, 2026
Anthem Biosciences Limited convened its 20th Annual General Meeting on July 22, 2026 via video conferencing and other audio-visual means, complying with requirements under the Companies Act and SEBI listing regulations. All directors, key auditors...
Anthem Biosciences Posts High Margins Amid Lower Q1 FY27 Revenues
Jul 21, 2026
Anthem Biosciences reported unaudited consolidated revenue from operations of ₹4,182 million for the quarter ended June 30, 2026, with its CRDMO business contributing ₹3,408 million and Specialty Ingredients ₹774 million. Total E...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.